Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LumeniX is a sublingual nutraceutical supplement developed by Entity Health, the nutraceutical division of the Australian pharmaceutical company iX Biopharma. The product's primary active ingredient is glutathione, a potent antioxidant. LumeniX is formulated using the proprietary WaferiX sublingual wafer technology, which is designed to enhance the absorption and bioavailability of glutathione by allowing it to dissolve under the tongue and enter the bloodstream directly, bypassing first-pass metabolism in the digestive system. It is marketed as a skin brightening and anti-aging supplement that reduces dark melanin production, improves skin luminosity, and diminishes fine lines and wrinkles. Additionally, it is promoted for immune support and may provide benefits for individuals with eczema.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LumeniX.